Prostate Cancer Treatments in 2026
Professor Phillip Stricker AO, MBBS(Hons), FRACS(Urology) is a urologist and one of the leading experts in the management and treatment of prostate cancer in Australasia. He is the Director of the St Vincent’s Prostate Cancer Centre, Chairman of the Department of Urology at St Vincent’s Private Hospital and Clinic and the Clinical Director of the Australian Prostate Cancer Research Centre in New South Wales (NSW). He is also a professor and associate professor at numerous recognised Institutions, University of Western Sydney, University of NSW and University of Sydney.
His clinical practice is dedicated to the management and treatment of prostate cancer, focusing on personalised care. This includes initial consultation, second opinions, therapy and follow-up of all post-treatment side effects, including erectile dysfunction and incontinence.
In 2006, Prof Stricker commenced the first robotic program using the latest technology (Da Vinci Si) in NSW at St Vincent’s Private Hospital. He has since performed almost 3000 robot-assisted radical prostatectomies. This is the second largest experience in Australia and the largest in NSW. In addition, previously, he has performed over 4000 open radical prostatectomies. This combined experience is the most in Australia. He also has extensive experience in performing high-dose rate brachytherapy (over 1000 cases), low-dose rate brachytherapy (over 1000 cases), designing and managing structured active surveillance programs and transperineal biopsies (over 10,000 cases).
Prof Stricker was the Head and Chairman of the Uro-oncology Multidisciplinary Team meetings for over 20 years.
He has been one of the Australian pioneers in the use of multiparametric MRI and PSMA-PET scan imaging and the introduction of focal therapy using irreversible electroporation-IRE (Nano-Knife) to treat prostate cancer, and has performed over 800 cases.
He mentors nationally and internationally, and has published over 40 articles on nanoknife technology and outcomes. He also has extensive experience in dealing with impotence and incontinence assessment, and treatments including penile prosthesis, sling surgery and artificial urinary sphincter surgery.
Professor Stricker’s area of research focuses on the collection of quality of life data following treatment in order to refine surgical techniques, the development and assessment of novel surgical techniques which are less invasive, the introduction of new technologies for treating prostate cancer, and the utilisation of medical imaging for the detection and evaluation of prostate cancer.
Professor Stricker was the driving force in setting up the St Vincent’s Prostate Cancer Clinical Database and Tissue Bank in conjunction with the Garvan Institute, which is currently housed at The Kinghorn Cancer Centre. These resources contain extensive clinical and pathological outcome data and have resulted in a comprehensive scientific and clinical resource that has been acknowledged both nationally and internationally.
Professor Stricker was a Member of the Australian Cancer Network working party that developed guidelines for the management of localised prostate cancer, metastatic prostate cancer, and PSA Testing. These guidelines have been published and are used as the evidence base in many publications. Professor Stricker has authored over 400 peer-reviewed publications.
Prostate Cancer Treatments in 2026
Professor Stricker's Team
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
A team of experienced professionals works together to guide you on your journey. This team includes surgeons, oncologists, physical therapists, sexual health advisors, mental health professionals and pelvic floor specialists.
I subspecialised in the area of prostate cancer about 30 years ago. And the reason I did that is because I felt that being an expert in one cancer was more important than being an expert in all cancers. And I felt that that's given my patients better options and better outcomes in terms of their treatment. I've been very, very involved in bringing new technologies such as transpirineal biopsy, brachytherapy, focal therapy, robotic surgery, and active surveillance to Australia, and more recently involved in bringing single port and tulsa to Australia. I've always been passionate about bringing things that might improve the outcomes of my prostate cancer patients. But I've also been very meticulous about ensuring that we do research, validated research, on all this information. And we've been very privileged to have the St. Vincent's Prostate Cancer Research Centre with all my collaborators, being able to do almost 300 international publications to make sure that we've been honest about the delivery of this care and honest about the outcomes, particularly when comparing different treatment options. So, in my hands now, I offer a patient who might come in with prostate cancer anything from active surveillance to robotic surgery to MR linac radiotherapy to brachytherapy or focal nanony therapy, and soon to include also tulsa therapy to maximize the treatment options that patients have. I'm in the privileged situation to have a fantastic team around me with a nurse who's been with me now for 35 years who carries a phone 24-7 and allows patients access to support while they're going through their cancer treatment. I've got an amazing administrative staff who are kind and receptive to the patients. I've got a research team with a chief research officer and a group of fellows who collect data on patients in an evidence-based way, often with ethics approval if it's a proper prospective study. And I also have an enormous relationship with the medical oncology department, the radiation department, the physiotherapy department who help with pelvic floor exercises, the psychology department who helped with support of people, and more recently the Men's Health Centre, which help people who can't afford all these other options at St. Vincent's Public Hospital, being a philanthropic hospital. I also am very lucky to have an incredibly skilled pathology department and a relationship with Professor Del Prado, which has gone on for over 30 years, and also been able to work with incredibly skilled radiologists and nuclear medicine physicians, including people such as Ron Schneer, Louise Emmett, and Sonny Ho, who've been able to accurately look at the imaging, which can become quite critical in the treatment of some patients. I've also been very lucky to have an incredibly good relationship with the Garvin Institute of Research, and that has led to one of the largest tissue banks and databases in the world. And that gives us the opportunity and researchers the opportunity to seamlessly go back and look at results to be able to find out and get insights into our prostate cancer patients. So, as you can see, it's not just one person doing the surgery or one person doing the focal therapy, it's a whole team of collaborators working together for you to ensure that you get the best possible outcomes and the best possible treatment.